OR WAIT null SECS
The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.
On July 10, 2018, Takeda Pharmaceutical announced that it received clearance from the United States Federal Trade Commission for its proposed $62-billion acquisition of Shire.
The acquisition, announced in May 2018, remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies. Under the terms of the agreement, each Shire shareholder will receive $30.33 in cash for each Shire share and Takeda shares. The boards of directors of both companies have approved the transaction, which is expected to close in the first half of 2019. Upon closing, Takeda shareholders will own approximately 50% of the combined group.
Shire is headquartered in Dublin, Ireland, and achieved more than $15 billion in 2017 revenues.
According to Takeda, the acquisition will strengthen its core therapeutic areas of oncology, gastrointestinal, and neuroscience and boosts Takeda’s position in specialized medicines through the addition of Shire’s global rare-disease franchise.
Source: Takeda Pharmaceutical